Transitioning sildenafil to taladafil in PAH patients is safe
Published: Sep 1, 2015
Abstract
Background: null Phosphodiesterase type-5 inhibitors (iPDE5) are one of the mainstays of Pulmonary Arterial Hypertension (PAH) treatment. Tadalafil is an alternative to sildenafil with the advantage of a less frequent dosing (once instead of 3-times daily). null null Aim: null To examine the feasibility of transitioning PAH patients from sildenafil to taladafil. null null Methods: null We studied twenty clinically stable PAH outpatients from a...
Paper Details
Title
Transitioning sildenafil to taladafil in PAH patients is safe
Published Date
Sep 1, 2015
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History